Azitra, Inc. announced positive results from ex vivo human skin studies on its ATR-COSF program, which uses a supernatant containing a recombinant human filaggrin protein to improve skin elasticity and reduce fine lines. The studies demonstrated effective penetration of the protein into skin layers and a dose-dependent increase in skin elasticity, with safety tests confirming the formulation is non-irritating. Azitra plans to optimize formulations and proceed to human trials to confirm visible wrinkle reduction benefits. This development could lead to a novel cosmetic ingredient enhancing skin firmness and appearance.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Alkane Resources generated A$102 million in mine operating cash flow and produced 40,740 gold equivalent ounces in the September quarter, supported by its three mines in Australia and Sweden. The company reported A$459 million in cash, bullion, and i...
